Myelofibrosis-Induced Erythropoietin-Resistant Anemia Due to Severe Refractory Hyperparathyroidism

Overview

Journal Kidney Int Rep

Publisher Elsevier

Specialty Nephrology

Date 2018 Jul 11

PMID 29988982

Citations 4

Authors

Sidharth Kumar Sethi

Shyam Bihari Bansal

Nikita Wadhwani

Mayur Makasana

Ashish Nandwani

Vijay Kher

Rupesh Raina

Affiliations

Soon will be listed here.

Citing Articles

Does Etelcalcetide reverse myelofibrotic bone changes due to hyperparathyroidism? A case report.

Panuccio V, Tripepi R, Postorino A, Greve B, Sabattini E, Oliva E Front Med (Lausanne). 2023; 9:1050062.

PMID: 36910010 PMC: 9995371. DOI: 10.3389/fmed.2022.1050062.

Case Report: Effects of Secondary Hyperparathyroidism Treatment on Improvement of Juvenile Nephronophthisis-Induced Pancytopenia and Myelofibrosis.

Amano K, Toyoda H, Nishikawa K, Murata T, Hirayama M Front Pediatr. 2021; 9:550158.

PMID: 34046371 PMC: 8144492. DOI: 10.3389/fped.2021.550158.

Iron Therapy in Chronic Kidney Disease: Days of Future Past.

Lee K, Ho Y, Tarng D Int J Mol Sci. 2021; 22(3).

PMID: 33498292 PMC: 7863960. DOI: 10.3390/ijms22031008.

Older Age and High Serum Ferritin Levels Associated With the Risk of Chronic Cytopenia in Hemodialysis Patients.

Lee Y, Wang W, Kuo C, Lee M, Lu Y, Hsiao C Front Med (Lausanne). 2020; 7:568350.

PMID: 33195315 PMC: 7662880. DOI: 10.3389/fmed.2020.568350.

References

Kruse A, Eisenberger U, Frey F, Mohaupt M . The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism. Nephrol Dial Transplant. 2005; 20(7):1311-4. DOI: 10.1093/ndt/gfh924. View

DAlessandro A, Melzer J, Pirsch J, Sollinger H, Kalayoglu M, Vernon W . Tertiary hyperparathyroidism after renal transplantation: operative indications. Surgery. 1989; 106(6):1049-55; discussion 1055-6. View

Szwarc I, Argiles A, Garrigue V, Delmas S, Chong G, Deleuze S . Cinacalcet chloride is efficient and safe in renal transplant recipients with posttransplant hyperparathyroidism. Transplantation. 2006; 82(5):675-80. DOI: 10.1097/01.tp.0000232452.80018.ad. View

Trovato G, Iannetti E, Carpinteri G . Systolic function impairment in higher erythropoietin requirement patients in hemodialysis. Recenti Prog Med. 1997; 88(5):217-22. View

Meytes D, Bogin E, Ma A, DUKES P, Massry S . Effect of parathyroid hormone on erythropoiesis. J Clin Invest. 1981; 67(5):1263-9. PMC: 370692. DOI: 10.1172/jci110154. View

Chertow G, Block G, Correa-Rotter R, Drueke T, Floege J, Goodman W . Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012; 367(26):2482-94. DOI: 10.1056/NEJMoa1205624. View

Zingraff J, Drueke T, Marie P, Man N, Jungers P, BORDIER P . Anemia and secondary hyperparathyroidism. Arch Intern Med. 1978; 138(11):1650-2. View

Sliem H, Tawfik G, Moustafa F, Zaki H . Relationship of associated secondary hyperparathyroidism to serum fibroblast growth factor-23 in end stage renal disease: a case-control study. Indian J Endocrinol Metab. 2011; 15(2):105-9. PMC: 3124995. DOI: 10.4103/2230-8210.81939. View

Barbour G . Effect of parathyroidectomy on anemia in chronic renal failure. Arch Intern Med. 1979; 139(8):889-91. View

10.

Bellavia M, Gioviale M, Damiano G, Palumbo V, Cacciabaudo F, Altomare R . Is secondary hyperparathyroidism-related myelofibrosis a negative prognostic factor for kidney transplant outcome?. Med Hypotheses. 2011; 77(4):557-9. DOI: 10.1016/j.mehy.2011.06.030. View

11.

Azevedo P, Cardoso P, Farah K, de Melo F, Rezende S . Complete reversal of bone marrow fibrosis after parathyroidectomy for secondary hyperparathyroidism. Br J Haematol. 2017; 178(4):500. DOI: 10.1111/bjh.14774. View

12.

Srinivas T, Schold J, Womer K, Kaplan B, Howard R, Bucci C . Improvement in hypercalcemia with cinacalcet after kidney transplantation. Clin J Am Soc Nephrol. 2007; 1(2):323-6. DOI: 10.2215/CJN.00500705. View

13.

Borchhardt K, Diarra D, Sulzbacher I, Benesch T, Haas M, Sunder-Plassmann G . Cinacalcet decreases bone formation rate in hypercalcemic hyperparathyroidism after kidney transplantation. Am J Nephrol. 2010; 31(6):482-9. DOI: 10.1159/000304180. View

14.

Isakova T, Nickolas T, Denburg M, Yarlagadda S, Weiner D, Gutierrez O . KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Am J Kidney Dis. 2017; 70(6):737-751. DOI: 10.1053/j.ajkd.2017.07.019. View

15.

McGonigle R, Wallin J, Husserl F, Deftos L, Rice J, ONeill Jr W . Potential role of parathyroid hormone as an inhibitor of erythropoiesis in the anemia of renal failure. J Lab Clin Med. 1984; 104(6):1016-26. View

16.

Leca N, Laftavi M, Gundroo A, Kohli R, Min I, KARAM J . Early and severe hyperparathyroidism associated with hypercalcemia after renal transplant treated with cinacalcet. Am J Transplant. 2006; 6(10):2391-5. DOI: 10.1111/j.1600-6143.2006.01475.x. View

17.

Rao D, SHIH M, Mohini R . Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med. 1993; 328(3):171-5. DOI: 10.1056/NEJM199301213280304. View

18.

Oliveira R, Cancela A, Graciolli F, Dos Reis L, Draibe S, Cuppari L . Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?. Clin J Am Soc Nephrol. 2009; 5(2):286-91. PMC: 2827593. DOI: 10.2215/CJN.05420709. View

19.

. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009; (113):S1-130. DOI: 10.1038/ki.2009.188. View

20.

Wesseling-Perry K, Bacchetta J . CKD-MBD after kidney transplantation. Pediatr Nephrol. 2011; 26(12):2143-51. PMC: 3203246. DOI: 10.1007/s00467-011-1829-6. View